Viridian Therapeutics, Inc. (NASDAQ: VRDN) reported Q1 EPS of ($0.79), $0.30 better than the analyst estimate of ($1.09). Revenue for the quarter came in at $72 thousand versus the consensus estimate of $138.1 thousand.

For earnings history and earnings-related data on Viridian Therapeutics, Inc. (VRDN) click here.